[Long-term follow-up and therapeutic control of a hepatic metastatic acinar cell carcinoma of the pancreas using FDG PET].
A 33 years old woman presented with cramp-like abdominal pain. Ultrasound examination revealed multiple lesions in the liver of hyper- and hypoechoic echogenicity which in accordance to subsequently performed computed tomography and dynamic hepatobiliary scintigraphy were considered to be a focal nodular hyperplasia (FNH). A severe increase of the serum lipase concentration, suspected to be an acute pancreatitis, was treated conservatively and led to a short improvement of symptoms. Some months later, a severe progression of the pain symptoms occurred, along with a measurable expansion of the abdominal circumference and palpable tumors of the liver. The dynamic hepatobiliary imaging and the static liver scan showed a decreased perfusion and function of the nodes as well as a reduced RES activity, respectively. A subsequently performed Positron Emission Tomography (PET) with F-18-Fluorodeoxyglucose (FDG) showed a massively increased glucose metabolism of the liver tumors. The histologic result of several biopsies of the tumors revealed metastases of an acinus cell carcinoma of the pancreas. Under systemic and local chemotherapy, a temporary remission could be obtained that was clearly detectable in a second FDG-PET. Nevertheless, during the further course of the disease, a progression occurred being detectable in an additional control PET-study by an increase in tumor size as well as in tumor glucose metabolism. The patient died in liver coma 15 months after the histologic diagnosis was obtained.
Rink
T
T
Klinik für Nuklearmedizin des Zentrums der Radiologie, Johann Wolfgang Goethe-Universität, Frankfurt am Main, Deutschland.
Schröder
O
O
Dietrich
C
C
Kirchner
J
J
Hör
G
G
Zeuzem
S
S
Baum
R P
RP
D000328:Adult; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D018267:Carcinoma, Acinar Cell / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000556:secondary*; D017809:Fatal Outcome; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000493:pharmacokinetics; D005472:Fluorouracil / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D002955:Leucovorin / Q000627:therapeutic use; D008113:Liver Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000556:secondary*; D010190:Pancreatic Neoplasms / Q000188:drug therapy / Q000473:pathology*; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D013997:Time Factors; D014055:Tomography, Emission-Computed; D014463:Ultrasonography
D000964:Antimetabolites, Antineoplastic; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; D002955:Leucovorin; D005472:Fluorouracil